HEALTHTECH COMPANY

TRANSFORMING STEM CELL THERAPY

TRANSFORMING STEM CELL THERAPY

without barriers to regenerative medicine

About Us

We are an early-stage healthtech company developing AI-powered cellular therapies for bone regeneration, born from the scientific and technological research of our founders

ADVANCED THERAPY MEDICAL PRODUCT | ALLOGENIC MESENCHYMAL STEM CELLS PLUS HYALURONIC ACID | EXTRACTION FROM UMBILICAL CORD | EX VIVO & SCALABLE PRODUCTION

Our Mission

To advance regenerative cell therapies for bone injuries, improving healing and quality of life without barriers.

R&D scalable therapies based on mesenchymal stem cells plus hyaluronic acid

Innovative Solutions for treating degenerative diseases and injuries through regenerative medicine

Strategic Partnership with hospitals and research centers to drive the expansion of health technologies

Diversified Revenue Model combining the sale of cutting-edge cellular therapies with ip licensing opportunities in global markets

Value Proposition

INTELLECTUAL PROPERTY

Argentina & PCT

Protocol Production

Ready to use solution without scaffold

Long Term Efficacy

Designed for lifelong effectiveness

Regulatory & Safety Prfile

Offering safety and efficacy

HYALURONIC ACID INNOVATION

Leveraging the Potential of Hyaluronic Acid

To advance regenerative cell
therapies for bone injuries

IMPROVING HEALING AND QUALITY OF LIFE WITHOUT BARRIERS

Timeline and Milestones, past and future

Next 2026
Expanded
FUTURE MILESTONES
  • Finalization of Clinical Study Design
  • First Patient Enrollment for Phase 1 Clinical Trial
  • Complete Phase 1 Clinical Trial
  • Development of Stem Cell Technology Platform
Next 2025
Expanded
REGULATORY APPROVALS
  • Regulatory Approval and Market Entry Strategy
  • Evaluation Request to ANMAT/INCUCAI for Clinical Application
October 24 - January 25
MVP Development
MVP DEVELOPMENT
  • Signature of R&D agreement with CONICET - UNNOBA
  • Signature of R&D agreement with Hosp. Garrahan
  • Product development under GMP in Hosp. Garrahan
December 23 - July 24
Agreements with collaborators
Agreements with collaborators
  • The Research Board of Hospital Garrahan approved the collaboration with the Cord Blood Bank
  • Term Sheet for the License Agreement signed with CONICET and UNNOBA
January 21 - October 23
Startup Creation Process
Startup Creation Process
  • Project Beginning
  • Approval by the SF500 Investment Committee
  • Registration Mesenchyal-T Inc

2021

Startup Creation Process

  • Project Beginning
  • Positive patentability evaluation by CONICET

02/2023

Startup Creation Process

  • SF500 BUILD Selection and participation

06/2023

Startup Creation Process

  • Patent aplication INPI
  • SF500 Investment commitee approva

10/2023

Startup Creation Process

  • Participation Regulatory. Assistance Prgogram AR R&D ANMAT
  • S.A registration Mesenchyal-T S.A

12/2023

Fundraising Agreements with collaborators

  • Aplication to EMPRETECNO 2023 (FONARSEC)
  • «Acelerar España 2023»

06/2024

Fundraising Agreements with collaborators

  • Patent Aplication PCT
  • Reseach board Hosp Garrahan aprobe the colaboration with cord bank

07/2024

Fundraising Agreements with collaborators

  • Signature of 75 license agreement CONICET – UNNOBA
  • Trademark registration INPI

10/2024

Fundrasing MVP Development

  • Signature of R&D agreement with CONICET – UNNOBA
  • Signature of R&D agreement with Hosp. Garraham

2024/25

Fundrasing MVP Development

  • Product development under GMP in Hosp. Garrhan
  • Product development under GMP in Hosp. Garrhan

Next 2025

Regulatory approvals Internationalazation

  • Signature of 75 license agreement CONICET – UNNOBA
  • Trademark registration INPI

Next 2025

Regulatory approvals Internationalazation

  • Signature of R&D agreement with CONICET – UNNOBA
  • Signature of R&D agreement with Hosp. Garraham

Next 2025

Regulatory approvals Internationalazation

  • Product development under GMP in Hosp. Garrhan
  • Product development under GMP in Hosp. Garrhan

Our Innovative
Solution

Is An Advanced Therapy Medicinal Product

Combines Allogenic Mesenchymal Stem Cells With Hyaluronic Acid

We Offer

To regenerate the bone naturally
To reduce time to restore bone fuction and mobility
To reduce treatment time with a single intervention
To reduce complications
AI platform to predict treatment outcomes

OUR TEAM

CONICET Researchers | PhDs | BSs in Genetics | Scientific Technological Entrepreneurs

FOUNDERS

alaniz
Alaniz, Laura
Co-Founder & CEO
icardi
Icardi, Antonella
Co-Founder & CEO
latina
Latina, Catalina
Cell Therapy Development

RESEARCH & DEVELOPMENT

vitale_3
Vitale, Daiana
Hyaluronic Acid Specialist
rosales_5
Rosales, Paolo
Inmunology & Biocompatibility
mantello
Mantello, Iván
IA & Software Development

ADVISORS

ferrari
Ferrari, José
Advisor
chiesa
Chiesa, Gaston
Advisor
garcia_4
García, Mariana
Advisor
picasso
Picasso, Ramiro
Advisor

JOIN OUR MISSION

Our Strategic Partnerships

Our team of investor partners, collaborators and sponsors.

SF500
PRIVATE INVESTMENT FUND | CREATES LIFE SCIENCE-BASED STARTUPS
Investment fund for high-impact scientific and technological startups
GARRAHAN
COLLABORATOR
Argentina's leading pediatric hospital, providing specialized medical care, research, and training in child health.
LOCILABS
COLLABORATOR
SPECIALIZED LABORATORY CO-WORKING
Business incubation services for technology-based companies
CONICET
SPONSOR INSTITUTION
Governmental organization dedicated to the promotion of science and technology in Argentina
UNNOBA
SPONSOR INSTITUTION
National University of Northwestern of Buenos Aires

News!

Latest posted updates!
post3
Laura Alaniz was invited to present our current proposal in
Biotechnological development at the «Open Innovation Hackathon 2024». 🎤💡Nuestra CEO Laura Alaniz fue...
post5
 Laura Alaniz (CEO ) y Antonella Icardi (CTO) participaron en la 12° edición de la muestra interactiva "TecUNNOBA" (2024), organizada por la UNNOBA.
 What are we looking for? To listen and learn from trauma specialists, who shared their clinical experience...
post2
 Opportunity to present our company MesencHyal-T to a traumamatology roundtable at La Pequeña Familia clinic.
 What are we looking for? To listen and learn from trauma specialists, who shared their clinical experience...
post4
 We took part in the "ANMAT Salud 2024 Conference: regulatory member ICH"
We took part in the «ANMAT Salud 2024 Conference: regulatory member ICH» organized by the National Academy...
post1
📢 MesencHyal-T at the III Multidisciplinary Congress of UNNOBA 🎓🔬
MesencHyal-T at the III Multidisciplinary Congress of UNNOBA We are pleased to share that the @MesencHyal-T...
post6
Nuestra CEO Laura Alaniz tuvo el honor de dar una charla sobre emprender y habilidades para el armado de una startup biotecnologica a jóvenes estudiantes
Nuestra CEO Laura Alaniz tuvo el honor de dar una charla sobre emprender y habilidades para el armado...
Transforming health with cell therapy innovation breaking down geographical and economic barriers